source
- Paragon spinout Velaris Therapeutics goes public via reverse merger with Alaunos, raising $350 millionParagon Labs, a biotechnology incubator, announced that its latest spinout, Velaris Therapeutics, became a public company through a reverse merger with Alaunos Therapeutics. The transaction places…
- BioNTech's mRNA cancer therapy fails to improve progression-free survival in head-neck cancer trialBioNTech reported that its experimental mRNA cancer immunotherapy, BNT 113, combined with Keytruda, did not meet the primary endpoint of progression-free survival in an interim analysis of a late-s…